Concepedia

Publication | Open Access

Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience

DOIFull Paper Access

42

Citations

19

References

2021

Year

Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum, Yaniv Lustig, Carmit Cohen, Galia Rahav, Keren Asraf, Sharon Amit, Hanaa Jaber, Ital Nemet,
The Journal of Infectious Diseases

Abstract

We demonstrate a rapid and broad immune response to the third BNT162b2 dose in individuals >60 years of age.

References

YearCitations

Page 1